Bolt Ebitda from 2010 to 2024

BOLT Stock  USD 0.60  0.02  3.45%   
Bolt Biotherapeutics EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA will likely drop to about -78.1 M in 2024. From the period from 2010 to 2024, Bolt Biotherapeutics EBITDA quarterly data regression had mean square error of 336.6 T and mean deviation of  28,057,164. View All Fundamentals
 
EBITDA  
First Reported
2019-12-31
Previous Quarter
-18.6 M
Current Value
-16 M
Quarterly Volatility
6.1 M
 
Covid
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Bolt Biotherapeutics Correlation against competitors.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Latest Bolt Biotherapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of Bolt Biotherapeutics over the last few years. It is Bolt Biotherapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Bolt Ebitda Regression Statistics

Arithmetic Mean(34,158,673)
Coefficient Of Variation(95.14)
Mean Deviation28,057,164
Median(11,174,000)
Standard Deviation32,498,156
Sample Variance1056.1T
Range80.4M
R-Value(0.84)
Mean Square Error336.6T
R-Squared0.70
Significance0.000092
Slope(6,097,570)
Total Sum of Squares14785.8T

Bolt Ebitda History

2024-78.1 M
2023-74.3 M
2022-88.7 M
2021-91.6 M
2020-48.6 M
2019-30.6 M

About Bolt Biotherapeutics Financial Statements

Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-74.3 M-78.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.